The Testosterone Debate: A Health Crisis for Cisgender Men and Its Implications for Transgender Care

A recent panel convened by the U.S. Food and Drug Administration (FDA) highlighted the growing concern over low testosterone levels in cisgender men, framing it as a significant health crisis. Experts argued for the deregulation of testosterone, suggesting that it should be more accessible at pharmacies without stigma. They emphasized that testosterone therapy could address common age-related ailments such as weight gain, loss of muscle mass, and fatigue, potentially preventing disease and premature death. However, the panel's focus on cisgender men's health has raised questions about the implications for transgender individuals seeking hormone therapy.

The Advocate

While the FDA panel presented a unified view on the benefits of testosterone for cisgender men, critics pointed out the hypocrisy in the contrasting treatment of testosterone for transgender individuals. Dr. Alex Dworak, a family medicine doctor, noted that the same medication is viewed differently depending on the patient's gender identity. He questioned why testosterone is considered beneficial for cisgender men but is met with skepticism when prescribed to transgender men. This sentiment was echoed by Zan Lussier, a transgender man, who highlighted the disparities in access to hormone therapy for cisgender and transgender individuals.

The Advocate

FDA Commissioner Dr. Marty Makary indicated that the agency is considering revisiting testosterone's classification as a controlled substance, which currently imposes restrictions on its prescription and refills. Shalin Shah, CEO of Marius Pharmaceuticals, urged the Department of Health and Human Services to recognize testosterone therapy as an essential health benefit, thereby reducing barriers to access. However, the Trump administration's recent rule changes have made it more difficult for transgender individuals to obtain gender-affirming care, raising concerns about the future of hormone therapy access.

The Advocate

Despite the panel's positive outlook, some medical experts, such as Dr. Adriane Fugh-Berman, criticized the lack of discussion regarding the risks associated with testosterone therapy, including high blood pressure and increased likelihood of blood clots. Fugh-Berman argued that the panel failed to provide sufficient evidence supporting claims that testosterone could prevent serious health conditions. Additionally, transgender individuals like Ashton Colby expressed anxiety over the potential loss of access to necessary hormone treatments, emphasizing the mental and physical toll of missing doses.

The Advocate

• “Testosterone therapy is safe, effective, and preventive,” — Dr. Helen Bernie, Associate Professor of Urology, Indiana University

The Advocate

• “I'm struck by the hypocrisy and the contradictions,” — Dr. Alex Dworak, Family Medicine Doctor

The Advocate

• “Without testosterone, I am not who I am,” he said.” — Zan Lussier, Transgender Man

The Advocate

The ongoing dialogue surrounding testosterone therapy highlights the need for a more inclusive approach to hormone treatment that recognizes the health needs of both cisgender and transgender individuals. As the FDA considers changes to testosterone's regulatory status, the implications for access to hormone therapy remain a critical concern for many. The intersection of health policy and gender identity continues to evolve, necessitating careful attention to the voices of all affected parties.

The Advocate